MPS advises of need for better awareness of cauda equina red flag symptoms

MPS advises of need for better awareness of cauda equina red flag symptoms

May 9 2018 The Medical Protection Society is advising doctors of a revision to the NICE Clinical...

Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 27 2018 Women and girls of childbearing potential must no longer take valproate medicines...

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

April 23 2018 Buprenorphine has been found to have lower rates of overdose death than methadone...

Class of diabetes drug linked to increased risk of irritable bowel disease

Class of diabetes drug linked to increased risk of irritable bowel disease

March 29 2018 A study has shown that dipeptidylpeptidase-4 inhibitors may increase the risk of...

  • MPS advises of need for better awareness of cauda equina red flag symptoms

    MPS advises of need for better awareness of cauda equina red flag symptoms

    Wednesday, 09 May 2018 16:01
  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:20
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Friday, 27 April 2018 12:12
  • Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Monday, 23 April 2018 16:59
  • Class of diabetes drug linked to increased risk of irritable bowel disease

    Class of diabetes drug linked to increased risk of irritable bowel disease

    Thursday, 29 March 2018 11:49

a man taking tablet imageApril 30 2018

Anticholinergic drugs used in helping control some involuntary muscle movement conditions have been found to be associated with an increased risk of dementia.

The study, described as the largest of its kind to date, has prompted researchers to say that clinicians should avoid long term prescribing of some anticholinergics to patients aged 45 and over. They should also “consider the risk of long term cognitive effects, as well as short term effects, associated with specific drug classes when performing their risk-benefit analysis.”

Researcher from the University of East Anglia assessed data from the UK’s Clinical Practice Research Database for 40,770 patients aged 65 to 99 years who were diagnosed with dementia between April 2006 and July 2015. Each case patient was matched to up to seven control patients of similar age and sex, but without dementia.

The researchers gave a score to drugs according to their anticholinergic activity using the Anticholinergic Cognitive Burden (ACB) scale. An ACB score of 1 was classed as possibly anticholinergic, while a score of 2 or 3 was definitely anticholinergic. Patient histories ranging from four to 20 years were then evaluated.

“When considered by drug class, gastrointestinal drugs with an ACB score of 3 were not distinctively linked to dementia. The risk of dementia increased with greater exposure for antidepressant, urological, and anti-Parkinson drugs with an ACB score of 3. This result was also observed for exposure 15-20 years before a diagnosis,” said the researchers.

“This could be caused by a class specific effect, or by drugs being used for very early symptoms of dementia” and they called for further research into the effects of specific drug classes.

Dr Doug Brown, Chief Policy and Research Officer at the Alzheimer’s Society, which funded the new study, said: “This large study confirms that some anticholinergic drugs can raise the risk of dementia – but it should put minds at ease as there appears to be no dementia risk with drugs used to treat common conditions like hay fever, travel sickness and stomach cramps.

“Current guidelines for doctors say that anticholinergic drugs should be avoided for frail older people because of their impact on memory and thinking, but doctors should consider these new findings for all over-65s as long-term use could raise the risk of dementia.”

Frequently prescribed anticholinergic drugs listed by Alzheimer’s UK included: 

  • anti-depressants – amitriptyline, dosulepin and paroxetine;
  • bladder medications – tolterodine, oxybutynin and solifenacin;
  • Parkinson’s treatment – procyclidine.

Parkinson’s UK has advised patients that “these drugs are old and are now rarely used for Parkinson’s. Sometimes they are prescribed for reducing tremor and muscle stiffness.

“One of the reasons that these medications are not often given to people with Parkinson's is because they can cause memory problems or make them worse. Anyone with Parkinson's who is taking anticholinergics should be carefully monitored by their specialist or Parkinson's nurse.”

Professor David Dexter, Deputy Research Director at Parkinson’s UK, added: “The research published this week shows us that there is a link between anticholinergic drugs and dementia but it does not tell us why. It could be that people who are in the very early stages of dementia are more likely to be prescribed these drugs for other reasons.

“It’s also important to point that other factors – such as unhealthy lifestyles – have a far greater impact on risk of dementia.”

Links:
BMJ announcement      
K Richardson et al. ‘Anticholinergic drugs and risk of dementia: case-control study’. BMJ 2018;361:k1315. Published 25 April 2018
Alzheimer’s UK announcement 
Parkinson’s UK announcement 

Clinical News

May 23 2018 Over 2,000 patients were removed from GP lists due to allegations of violence or threats in 2017. A further 10,000 were removed due to a break down in the relationship between the GP and...
May 18 2018 New guidance to support the integration of community pharmacy services into primary care homes (PCHs) has been published.  The National Association of Primary Care’s report looks at ways...